SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-000643 to Cingulate Inc. (CING)

Cingulate Inc.
Date: Jan. 18, 2024 · CIK: 0001862150 · Accession: 0000000000-24-000643

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-276502

Date
January 18, 2024
Author
Shane Schaffer
Form
UPLOAD
Company
Cingulate Inc.

Letter

United States securities and exchange commission logo January 18, 2024 Shane Schaffer Chief Executive Officer Cingulate Inc. 1901 W. 47th Place Kansas City , KS 66205 Re:Cingulate Inc. Registration Statement on Form S-1 Filed January 12, 2024 File No. 333-276502 Dear Shane Schaffer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steve Skolnick, Esq.

Show Raw Text
United States securities and exchange commission logo
January 18, 2024
Shane Schaffer
Chief Executive Officer
Cingulate Inc.
1901 W. 47th Place
Kansas City , KS 66205
Re:Cingulate Inc.
Registration Statement on Form S-1
Filed January 12, 2024
File No. 333-276502
Dear Shane Schaffer:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Steve Skolnick, Esq.